Profile data is unavailable for this security.
About the company
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
- Revenue in USD (TTM)68.68m
- Net income in USD-60.84m
- Incorporated2013
- Employees279.00
- LocationPulmonx Corp700 Chesapeake DrREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 934-2600
- Fax+1 (302) 655-5049
- Websitehttps://pulmonx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akoya Biosciences Inc | 96.63m | -63.32m | 197.05m | 330.00 | -- | 3.66 | -- | 2.04 | -1.48 | -1.48 | 2.18 | 1.09 | 0.5423 | 2.49 | 7.23 | 292,827.30 | -35.53 | -- | -44.59 | -- | 58.27 | -- | -65.53 | -- | 2.94 | -10.94 | 0.5882 | -- | 29.09 | -- | 10.36 | -- | -- | -- |
| Stereotaxis Inc | 26.77m | -22.06m | 221.75m | 122.00 | -- | 13.37 | -- | 8.28 | -0.2737 | -0.2737 | 0.3318 | 0.2708 | 0.5617 | 1.46 | 6.01 | 219,434.40 | -43.46 | -25.02 | -61.11 | -34.12 | 55.51 | 67.57 | -77.37 | -41.90 | 1.88 | -- | 0.00 | -- | -4.89 | -1.82 | -12.33 | -- | 6.63 | -- |
| Accuray Inc | 447.48m | -14.55m | 229.08m | 1.02k | -- | 4.81 | -- | 0.5119 | -0.1496 | -0.1496 | 4.62 | 0.4806 | 0.9469 | 1.90 | 5.37 | 436,994.20 | -3.08 | -1.45 | -5.28 | -2.48 | 33.97 | 37.86 | -3.25 | -1.62 | 0.8406 | 0.3262 | 0.7857 | -- | 4.12 | 2.03 | -73.56 | -- | 13.92 | -- |
| Senseonics Holdings Inc | 22.39m | -60.39m | 231.96m | 132.00 | -- | 6.48 | -- | 10.36 | -0.1023 | -0.1023 | 0.0387 | 0.1385 | 0.1418 | 2.40 | 6.41 | 169,621.20 | -38.24 | -73.65 | -45.21 | -106.97 | 13.81 | -40.41 | -269.73 | -649.86 | 7.03 | -- | 0.3593 | -- | 36.62 | 3.43 | -142.49 | -- | -18.76 | -- |
| Utah Medical Products, Inc. | 50.22m | 16.64m | 245.27m | 169.00 | 14.94 | 1.93 | 10.69 | 4.88 | 4.57 | 4.57 | 13.81 | 35.35 | 0.3873 | 2.19 | 11.25 | 297,183.40 | 12.83 | 12.69 | 13.38 | 13.19 | 59.81 | 61.57 | 33.12 | 30.51 | 20.53 | -- | 0.00 | 37.05 | -3.93 | 3.64 | 0.9834 | 1.65 | 9.71 | 1.86 |
| AngioDynamics, Inc. | 324.01m | -192.37m | 252.74m | 815.00 | -- | 1.17 | -- | 0.7801 | -4.78 | -4.78 | 8.10 | 5.41 | 0.7468 | 2.66 | 6.46 | 397,555.80 | -44.34 | -9.12 | -54.02 | -10.17 | 50.17 | 54.23 | -59.37 | -19.48 | 1.62 | -- | 0.00 | -- | 7.13 | 5.30 | -97.54 | -- | 3.55 | -- |
| Sight Sciences Inc | 81.06m | -55.55m | 274.03m | 214.00 | -- | 2.26 | -- | 3.38 | -1.14 | -1.14 | 1.67 | 2.45 | 0.4269 | 1.70 | 5.51 | 378,761.70 | -29.26 | -38.78 | -31.77 | -42.20 | 85.34 | 80.74 | -68.53 | -105.14 | 12.65 | -10.59 | 0.2201 | -- | 13.63 | 60.84 | 35.59 | -- | 6.77 | -- |
| Edap Tms SA (ADR) | 64.18m | -22.50m | 275.68m | 307.00 | -- | 4.56 | -- | 4.30 | -0.6082 | -0.6082 | 1.73 | 1.63 | 0.6272 | 2.68 | 3.86 | 209,060.20 | -21.98 | -6.62 | -29.54 | -9.22 | 40.40 | 43.23 | -35.05 | -9.59 | 2.30 | -27.44 | 0.1045 | -- | 9.64 | 9.05 | -622.06 | -- | 32.75 | -- |
| Pulmonx Corp | 68.68m | -60.84m | 289.92m | 279.00 | -- | 2.43 | -- | 4.22 | -1.60 | -1.60 | 1.81 | 3.07 | 0.3698 | 1.14 | 6.61 | 246,147.00 | -32.76 | -26.27 | -36.90 | -28.97 | 73.90 | 71.95 | -88.60 | -93.76 | 5.77 | -- | 0.2394 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| AxoGen Inc | 159.01m | -21.72m | 303.74m | 426.00 | -- | 3.17 | -- | 1.91 | -0.5070 | -0.5070 | 3.71 | 2.22 | 0.8108 | 1.63 | 6.72 | 373,267.60 | -11.07 | -13.92 | -12.85 | -15.84 | 78.46 | 79.74 | -13.66 | -20.28 | 2.14 | -- | 0.3277 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Tactile Systems Technology Inc | 274.42m | 28.52m | 335.01m | 992.00 | 11.87 | 1.72 | 9.56 | 1.22 | 1.19 | 1.19 | 11.90 | 8.20 | 1.02 | 6.02 | 5.60 | 276,636.10 | 10.63 | 0.9015 | 13.23 | 1.09 | 49.95 | 49.10 | 10.39 | 0.8309 | 2.99 | -- | 0.1308 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| CVRx Inc | 39.30m | -41.20m | 348.03m | 200.00 | -- | 4.57 | -- | 8.86 | -1.99 | -1.99 | 1.89 | 3.64 | 0.3272 | 0.6974 | 6.02 | 196,475.00 | -34.31 | -- | -36.75 | -- | 84.08 | -- | -104.85 | -- | 12.86 | -23.96 | 0.2779 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Bioventus Inc | 502.76m | -122.57m | 366.54m | 970.00 | -- | 2.05 | -- | 0.729 | -1.97 | -2.93 | 8.06 | 2.25 | 0.4552 | 2.14 | 4.10 | 448,889.30 | -14.34 | -- | -18.91 | -- | 62.87 | 70.26 | -31.51 | -9.18 | 0.9443 | 0.3731 | 0.6354 | -- | 18.85 | 11.89 | -919.12 | -- | -- | -- |
| Surmodics Inc | 138.20m | 5.52m | 376.12m | 376.00 | 67.56 | 3.08 | 26.39 | 2.72 | 0.3911 | 0.3911 | 9.82 | 8.58 | 0.7897 | 2.10 | 7.05 | 367,561.20 | 3.15 | -1.85 | 3.49 | -2.18 | 79.38 | 82.93 | 3.99 | -2.98 | 3.97 | 5.84 | 0.1942 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Neuropace Inc | 65.42m | -32.96m | 379.82m | 171.00 | -- | 18.05 | -- | 5.81 | -1.28 | -1.28 | 2.53 | 0.7423 | 0.590 | 1.65 | 6.61 | 382,578.90 | -29.72 | -- | -33.88 | -- | 73.56 | -- | -50.38 | -- | 5.02 | -4.97 | 0.7339 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| Zynex Inc | 184.32m | 9.73m | 381.88m | 1.10k | 44.67 | 8.67 | 27.37 | 2.07 | 0.2677 | 0.2677 | 5.10 | 1.38 | 1.45 | 2.86 | 5.96 | 167,565.50 | 7.68 | 14.58 | 9.11 | 17.52 | 79.38 | 79.62 | 5.28 | 10.44 | 4.03 | 9.85 | 0.5581 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
Data as of Apr 16 2024. Currency figures normalised to Pulmonx Corp's reporting currency: US Dollar USD
54.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 31 Dec 2023 | 5.65m | 14.65% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.98m | 7.73% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.47m | 6.42% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.97m | 5.11% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.85m | 4.81% |
| Point72 Asset Management LPas of 28 Feb 2024 | 1.84m | 4.76% |
| Divisadero Street Capital Management LPas of 31 Dec 2023 | 1.41m | 3.65% |
| BNP Paribas Asset Management USA, Inc.as of 31 Dec 2023 | 929.59k | 2.41% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 874.97k | 2.27% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2023 | 853.85k | 2.22% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
